Summary："Breakthrough AML Treatment Shows Remarkable Survival Benefits in Groundbreaking Phase II Trial"HONG

"Breakthrough AML Treatment Shows Remarkable Survival Benefits in Groundbreaking Phase II Trial"

HONG KONG, June 17, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") today announced that compelling results from its randomized, double-blind, placebo-controlled Phase II trial (AK117-206) of ligufalimab (AK117) were presented as an oral presentation at a prestigious medical conference, marking a significant milestone in the treatment of Acute Myeloid Leukemia (AML). The innovative therapy has demonstrated remarkable survival benefits, revolutionizing the prospects for patients battling this aggressive blood cancer.

The Phase II trial, which enrolled patients with newly diagnosed AML, revealed that ligufalimab, when used in conjunction with standard chemotherapy, substantially improved overall survival rates compared to the placebo group. Notably, the treatment also exhibited a favorable safety profile, with manageable adverse events. These findings underscore the potential of ligufalimab to become a cornerstone in AML treatment, addressing a significant unmet medical need.

Industry experts are hailing the results as a major breakthrough, given the historically poor prognosis associated with AML. The introduction of ligufalimab could significantly alter the treatment paradigm, offering new hope to patients and clinicians alike. With AML being one of the most common types of leukemia in adults, the impact of this development is expected to be far-reaching. Analysts predict that Akeso's innovative therapy could capture a substantial share of the oncology market, driven by its efficacy and safety advantages.

As ligufalimab advances to the next stage of clinical development, stakeholders are eagerly anticipating the potential for regulatory approval and subsequent commercialization. Akeso's commitment to addressing the unmet needs in the oncology community is evident through its robust pipeline and dedication to innovative research. The success of ligufalimab could also pave the way for further exploration of its applications in other hematological malignancies.

In conclusion, the outstanding results from the Phase II trial of ligufalimab represent a significant leap forward in the treatment of AML. With its potential to improve patient outcomes and transform the therapeutic landscape, ligufalimab is poised to make a lasting impact on the oncology community. As the medical community continues to scrutinize the data and await further developments, one thing is clear: ligufalimab has the potential to be a game-changer in the fight against AML.